Compositions and methods for treatment of exocrine pancreatic insufficiency (EPI)
A method of treating exocrine pancreatic insufficiency includes administering to an individual in need thereof (e.g., an individual with cystic fibrosis) an effective amount of an enteral composition having a total protein consisting essentially of hydrolyzed protein and a total fat containing monoacylglycerols (MAG) that are at least about 30 wt. % of the total fat, and the total fat optionally further contains medium chain triglycerides (MCT) and/or fatty acids. In one particular non-limiting embodiment, about 60 wt. % of the total fat is from MCT and about 40 wt. % of the total fat is from MAG; in another particular non-limiting embodiment, the total fat is MAG with free fatty acids (esterified and/or bound) without MCT; and in yet another particular non-limiting embodiment, the total fat is MAG alone without MCT.
1. A method of treating exocrine pancreatic insufficiency (EPI), the method comprising administering to an individual in need thereof an effective amount of a nutritional composition having (1) a total protein consisting essentially of hydrolyzed protein and (2) a total fat comprising monoacylglycerols (MAG) that are at least about 30 wt % of the total fat, the total fat optionally further comprising medium chain triglycerides (MCT) and/or fatty acids, wherein the nutritional composition has an energy density of 1.0-2.0 kcal/ml.
2. The method of claim 1 , the method comprising administering to the individual the nutritional composition having at least one characteristic selected from the group consisting of:
(i) an energy density of 1.0-1.5 kcal/ml;
(ii) the total fat that is about 10 to about 90 energy % of the nutritional composition;
(iii) an amount of medium chain triglycerides (MCT) that is about 1.0 wt % to about 10.0 wt % of the nutritional composition;
(iv) the MAG that are about 0.1 wt % to about 10.0 wt % of the nutritional composition;
(v) the total protein that is about 5 to about 50 energy % of the nutritional composition;
(vi) a total carbohydrates that is about 5 to about 85 energy % of the nutritional composition; and
(vii) the total carbohydrates that consist essentially of one or more of maltodextrin, maltose, maltotriose, sucrose, fructose, lactose, galactose, and high-maltose corn syrup, and optionally comprise slowly digested carbohydrates.
3. The method of claim 1 , the method comprising administering to the individual the nutritional composition having the total fat further comprising an additional fat that is selected from the group consisting of diacylglycerols (DAG), long chain triglycerides (LCT), medium chain triglycerides (MCT), short chain fatty acids (SCFA), branched chain fatty acids (BCFA), structured MAG, structured DAG, free fatty acids, bound fatty acids, phospholipids, lyso-phospholipids, sphingomyelin, gangliosides, specialized pro-resolving mediators (SPMs), and mixtures thereof.
4. The method of claim 1 , further comprising detecting the EPI in the patient before the administering the nutritional composition to the individual.
5. The method of claim 1 , the method comprising administering to the individual the nutritional composition having the total fat comprising the MAG that is at least 40 wt % of the total fat.
6. The method of claim 1 , the method comprising administering to the individual the nutritional composition having the total fat that comprises the MAG; and further comprises LCT in an amount from 10 wt % to 30 wt % of the total fat.
7. The method of claim 1 , the method comprising administering to the individual the nutritional composition having the total fat that comprises the MAG; and further comprises less than 5.0 wt % LCT relative to the total fat.
8. The method of claim 1 , the method comprising administering to the individual the nutritional composition having the total fat comprising a combination of free fatty acids and the MAG.
9. The method of claim 2 , the method comprising administering to the individual the nutritional composition having at least one characteristic selected from the group consisting of: (i) an energy density of 1.0-1.5 kcal/ml; (ii) the total fat that is about 10 to about 90 energy % of the nutritional composition; (iii) an amount of the MCT that is about 1.0 wt % to about 10.0 wt % of the nutritional composition; (iv) the MAG that are about 0.1 wt % to about 10.0 wt % of the nutritional composition; (v) the total protein that is about 5 to about 50 energy % of the nutritional composition; (vi) a total carbohydrates that is about 5 to about 85 energy % of the nutritional composition; and (vii) the total carbohydrates that consist essentially of one or more of maltodextrin, maltose, maltotriose, sucrose, fructose, lactose, galactose, and high-maltose corn syrup, and optionally comprise isomaltulose.
10. A method of treating exocrine pancreatic insufficiency (EPI), the method comprising administering to an individual in need thereof an effective amount of a nutritional composition having (1) a total protein consisting essentially of hydrolyzed protein and (2) a total fat comprising monoacylglycerols (MAG) that are at least about 30 wt % of the total fat, the total fat further comprising medium chain triglycerides (MCT) and optionally comprising fatty acids, wherein the nutritional composition comprises characteristics of:
(i) an energy density of 1.0-2.5 kcal/ml;
(ii) the total fat that is about 10 to about 90 energy % of the nutritional composition;
(iii) an amount of the MCT that is about 1.0 wt % to about 10.0 wt % of the nutritional composition;
(iv) the MAG that are about 0.1 wt % to about 10.0 wt % of the nutritional composition;
(v) the total protein that is about 5 to about 50 energy % of the nutritional composition;
(vi) a total carbohydrates that is about 5 to about 85 energy % of the nutritional composition; and
(vii) the total carbohydrates that consist essentially of one or more of maltodextrin, maltose, maltotriose, sucrose, fructose, lactose, galactose, and high-maltose corn syrup, and optionally comprise slowly digested carbohydrates.
11. A method of treating exocrine pancreatic insufficiency (EPI), the method comprising administering to an individual in need thereof an effective amount of a nutritional composition having (1) a total protein consisting essentially of hydrolyzed protein and (2) a total fat comprising monoacylglycerols (MAG) that are at least about 30 wt % of the total fat, the total fat optionally further comprising medium chain triglycerides (MCT) and/or fatty acids, wherein the nutritional composition does not contain any phospholipids.